Safety Study of Ciprofloxacin in Newborn Mice.
Thomas Bourgeois,Anne-Lise Delezoide,Wei Zhao,Fabien Guimiot,Homa Adle-Biassette,Estelle Durand,Maud Ringot,Jorge Gallego,Thomas Storme,Chantal Le Guellec,Behrouz Kassai,Mark A. Turner,Evelyne Jacqz-Aigrain,Boris Matrot
DOI: https://doi.org/10.1016/j.yrtph.2015.11.002
IF: 3.598
2016-01-01
Regulatory Toxicology and Pharmacology
Abstract:Ciprofloxacin, a broad-spectrum antimicrobial agent belonging to the fluoroquinolone family, is prescribed off-label in infants less than one year of age. Ciprofloxacin is included in the European Medicines Agency priority list of off-patent medicinal products requiring evaluation in neonates. This evaluation is undergoing within the TINN (Treat Infections in Neonates) FP7 EU project. As part of the TINN project, the present preclinical study was designed to assess the potential adverse effects of Ciprofloxacin on neurodevelopment, liver and joints in mice. Newborn mice received subcutaneous Ciprofloxacin at 10, 30 and 100 mg/kg/day from 2 to 12 postnatal days. Peak plasma levels of Ciprofloxacin were in the range of levels measured in human neonates. We examined vital functions in vivo, including cardiorespiratory parameters and temperature, psychomotor development, exploratory behavior, arthro-, nephro- and hepato-toxic effects. We found no effect of Ciprofloxacin at 10 and 30 mg/kg/day. In contrast, administration at 100 mg/kg/day delayed weight gain, impaired cardiorespiratory and psychomotor development, caused inflammatory infiltrates in the connective tissues surrounding the knee joint, and moderately increased extramedullary hematopoiesis. The present study pleads for careful watching of cardiorespiratory and motor development in neonates treated with Ciprofloxacin, in addition to the standard surveillance of arthrotoxicity.